Mizuho Securities Reiterates Buy Rating on Arcutis Biotherapeutics (ARQT), "Like the Risk/Reward Setup" Heading Into Multiple Catalysts
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $57.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
